The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1477-7819

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis ; volume:18 ; number:1 ; day:3 ; month:7 ; year:2020 ; pages:1-11 ; date:12.2020
World journal of surgical oncology ; 18, Heft 1 (3.7.2020), 1-11, 12.2020

Creator: Chen, Jingjie
Li, Shengnan
Yao, Qigu
Du, Nannan
Fu, Xiaojun
Lou, Yuanmei
Wang, Mengru
Mao, Feiyan
Mao, Danyi
Khadaroo, Parikshit Asutosh
Tang, Yingying

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12957-020-01933-5

URN: urn:nbn:de:101:1-2020083121285483572688

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 9:00 AM UTC

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Chen, Jingjie
Li, Shengnan
Yao, Qigu
Du, Nannan
Fu, Xiaojun
Lou, Yuanmei
Wang, Mengru
Mao, Feiyan
Mao, Danyi
Khadaroo, Parikshit Asutosh
Tang, Yingying
SpringerLink (Online service)

Other Objects (12)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Hochschulschrift

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Hochschulschrift

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Hochschulschrift

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Related objects

Reset password